<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03050060</url>
  </required_header>
  <id_info>
    <org_study_id>9712</org_study_id>
    <secondary_id>NCI-2016-01816</secondary_id>
    <secondary_id>9712</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG3117000</secondary_id>
    <nct_id>NCT03050060</nct_id>
  </id_info>
  <brief_title>Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer</brief_title>
  <official_title>ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy With Concurrent Nelfinavir and Immunotherapy in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well image guided hypofractionated radiation therapy works&#xD;
      with nelfinavir mesylate, pembrolizumab, nivolumab, and atezolizumab in treating patients&#xD;
      with melanoma, lung cancer, or kidney cancer that has spread (advanced). Hypofractionated&#xD;
      radiation therapy delivers higher doses of radiation therapy over a shorter period of time&#xD;
      and may kill more tumor cells and have fewer side effects. Nelfinavir mesylate may stop the&#xD;
      growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy&#xD;
      with monoclonal antibodies, such as pembrolizumab, nivolumab and atezolizumab, may help the&#xD;
      body's immune system attack the cancer, and may interfere with the ability of tumor cells to&#xD;
      grow and spread. Giving hypofractionated radiation therapy, nelfinavir mesylate,&#xD;
      pembrolizumab, nivolumab and atezolizumab may work better in treating patients with melanoma,&#xD;
      lung, or kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Beginning 7-14 days prior to start of pembrolizumab, nivolumab, or atezolizumab, patients&#xD;
      receive nelfinavir mesylate orally (PO) twice daily (BID) on days 1-7 or 1-14 (dependent upon&#xD;
      when treatment is started) up to 11-12 weeks. Patients also receive pembrolizumab, nivolumab&#xD;
      or atezolizumab intravenously (IV) over 30-60 minutes on day 1. Cycles repeat every 21-28&#xD;
      days in the absence of disease progression or unacceptable toxicity. Patients then undergo&#xD;
      hypofractionated radiation therapy over 3-14 days starting after cycle 1 and before cycle 3&#xD;
      of pembrolizumab, nivolumab or atezolizumab.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and then every 6&#xD;
      months for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Actual">October 1, 2018</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined by immune-related Response Evaluation Criteria in Solid Tumor 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From start of study treatment to death due to any cause, assessed up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From start of treatment to progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, symptomatic deterioration, or death due to any cause, assessed up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune correlative studies including changes in T-cell repertoire</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Metastatic Kidney Carcinoma</condition>
  <condition>Recurrent Lung Non-Small Cell Carcinoma</condition>
  <condition>Stage IV Cutaneous Melanoma AJCC v6 and v7</condition>
  <condition>Stage IV Renal Cell Cancer AJCC v7</condition>
  <condition>Stage IV Lung Non-Small Cell Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (nelfinavir, immunotherapy, radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 7-14 days prior to start of pembrolizumab, nivolumab, or atezolizumab, patients receive nelfinavir mesylate PO BID on days 1-7 or 1-14 (dependent upon when treatment is started) up to 11-12 weeks. Patients also receive pembrolizumab, nivolumab or atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21-28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo hypofractionated radiation therapy over 3-14 days starting after cycle 1 and before cycle 3 of pembrolizumab, nivolumab or atezolizumab. The study will exclude irradiation of liver metastases as an added precaution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nelfinavir, immunotherapy, radiation therapy)</arm_group_label>
    <other_name>MPDL 3280A</other_name>
    <other_name>MPDL 328OA</other_name>
    <other_name>MPDL-3280A</other_name>
    <other_name>MPDL3280A</other_name>
    <other_name>MPDL328OA</other_name>
    <other_name>RG7446</other_name>
    <other_name>RO5541267</other_name>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Radiation Therapy</intervention_name>
    <description>Undergo hypofractionated radiation therapy</description>
    <arm_group_label>Treatment (nelfinavir, immunotherapy, radiation therapy)</arm_group_label>
    <other_name>Hypofractionated Radiotherapy</other_name>
    <other_name>hypofractionation</other_name>
    <other_name>Radiation, Hypofractionated</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (nelfinavir, immunotherapy, radiation therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir Mesylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (nelfinavir, immunotherapy, radiation therapy)</arm_group_label>
    <other_name>AG1343</other_name>
    <other_name>Viracept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nelfinavir, immunotherapy, radiation therapy)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nelfinavir, immunotherapy, radiation therapy)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease eligibility and stage&#xD;
&#xD;
               -  Histologically confirmed diagnosis of melanoma, non-small cell lung cancer&#xD;
                  (NSCLC), or renal carcinoma&#xD;
&#xD;
               -  Previously treated or previously untreated stage IV melanoma, stage IV or&#xD;
                  recurrent lung cancer, and metastatic renal cancer by American Joint Committee on&#xD;
                  Cancer (AJCC) staging criteria&#xD;
&#xD;
               -  Presence of a lesion that is suitable for hypofractionated radiotherapy&#xD;
&#xD;
          -  Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) criteria independent of the lesion to be irradiated. Prior checkpoint&#xD;
             inhibitor immunotherapy or chemotherapy is allowed as long as the last dose was&#xD;
             received &gt; 14 days prior to enrollment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
          -  Acceptable marrow function and hematologic indices for PD1/PDL1 immune checkpoint&#xD;
             inhibitor and nelfinavir as per standard of care&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have had immunotherapy, chemotherapy, or radiation therapy within 14 days&#xD;
             (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who&#xD;
             have not recovered from adverse events due to agents administered more than 4 weeks&#xD;
             earlier&#xD;
&#xD;
          -  Subjects may not be receiving other investigational agents&#xD;
&#xD;
          -  Patients with untreated/active brain metastases as documented by computed tomography&#xD;
             (CT) or magnetic resonance imaging (MRI) within 2 months of study enrollment; by&#xD;
             active brain metastases - we mean - actively symptomatic brain metastases requiring&#xD;
             steroids&#xD;
&#xD;
          -  Allergy or intolerance to nelfinavir or selected PD1/PDL1 immune checkpoint inhibitor&#xD;
&#xD;
          -  Patients requiring steroids or other immunosuppressive therapy; low-dose or topical&#xD;
             steroids are allowable if being used as replacement therapy&#xD;
&#xD;
          -  Patients receiving anti-retroviral therapy or other agents that are contra-indicated&#xD;
             with nelfinavir due to drug-drug interactions*&#xD;
&#xD;
          -  Pregnant or lactating patients&#xD;
&#xD;
          -  Prior radiation that precludes delivery of hypofractionated radiotherapy&#xD;
&#xD;
               -  *For a study regarding the safety and efficacy of high dose nelfinavir on&#xD;
                  patients with Kaposi's Sarcoma (KS), exclusion criteria included participants who&#xD;
                  were receiving any &quot;strong inhibitors or inducers of cytochrome P450, family 3,&#xD;
                  subfamily A (CYP3A) or cytochrome P450, family 2, subfamily C, polypeptide 19&#xD;
                  (2C19)&quot;&#xD;
&#xD;
        Strong Inhibitors of CYP3A4:&#xD;
&#xD;
          -  Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin&#xD;
&#xD;
          -  HIV: non-nucleoside reverse transcriptase inhibitors (delavirdine, nevirapine),&#xD;
             protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir),&#xD;
             cobicistat-boosted antiretrovirals (e.g., elvitegravir); NOTE: Clinical trials have&#xD;
             demonstrated that there are no clinically significant drug-drug interactions between&#xD;
             nelfinavir and the following antiretrovirals: efavirenz (strong CYP3A4 inhibitor),&#xD;
             etravirine (strong CYP3A4 inhibitor); therefore, these antiretrovirals will not be&#xD;
             excluded. • Antifungals: itraconazole, ketoconazole, voriconazole, fluconazole,&#xD;
             posaconazole&#xD;
&#xD;
          -  Antidepressants: nefazodone&#xD;
&#xD;
          -  Antidiuretic: conivaptan&#xD;
&#xD;
          -  GI: cimetidine, aprepitant&#xD;
&#xD;
          -  Hepatitis C: boceprevir, telaprevir&#xD;
&#xD;
          -  Miscellaneous: seville oranges, grapefruit, or grapefruit juice and/or pomelos, star&#xD;
             fruit, exotic citrus fruits, or grapefruit hybrids.&#xD;
&#xD;
        Strong Inducers of CYP3A4:&#xD;
&#xD;
          -  Glucocorticoids: cortisone (&gt; 50 mg), hydrocortisone (&gt; 40 mg), prednisone (&gt; 10 mg),&#xD;
             methylprednisolone (&gt; 8 mg), dexamethasone (&gt; 1.5 mg)&#xD;
&#xD;
          -  Anticonvulsants: phenytoin, carbamazepine, primidone, phenobarbital and other enzyme&#xD;
             inducing anti-convulsant drugs (EIACD)&#xD;
&#xD;
          -  Antibiotics: rifampin (rifampicin), rifabutin, rifapentine&#xD;
&#xD;
          -  Miscellaneous: St. John's Wort, modafinil&#xD;
&#xD;
        Strong Inhibitors of CYP2C9:&#xD;
&#xD;
        • Antifungals: fluconazole; lists including medications and substances known or with the&#xD;
        potential to interact with the CYP3A or 2C19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramesh Rengan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <disposition_first_submitted>September 30, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 5, 2021</disposition_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Ramesh Rengan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>Lung</keyword>
  <keyword>Melanoma, Skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

